Overview

Efficacy and Safety Study of SUNPG1623

Status:
Completed
Trial end date:
2019-09-24
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
Phase:
Phase 2
Details
Lead Sponsor:
Sun Pharma Global FZE
Sun Pharmaceutical Industries Limited